Sign Up
SB 1355 Connecticut Senate · 2025 Regular Session

AN ACT CONCERNING PRESCRIPTION DRUGS, DEVICES AND NONLEGEND DRUGS.

SB 1355 regulates two key areas of pharmacy practice. It requires the state to maintain patient access to specific drugs - including mifepristone, misoprostol, and similar medications - by allowing their import and ensuring nonsterile compounding pharmacies follow safety standards. The bill also mandates pharmaceutical companies to register annually as "marketing firms" with the state, pay a $150 fee, and report details about representatives' interactions with healthcare providers, such as contact counts and whether samples or gifts were provided. These provisions directly affect compounding pharmacies, pharmaceutical manufacturers, and healthcare providers.
Issues: ✓ HealthcareSupports HealthcareMandates patient access to specific drugs (including mifepristone) and sets pharmacy safety standards, improving healthcare access and safety.95% confidence
Sub-Topics: Prescription Drugs
Bill status passed both 4 of 5 stages cleared
Introduction
Feb 2025
Committee Review
May 2025
Senate Passage
May 2025
House Passage
Jun 2025
Governor
Introduced Feb 20, 2025 Last action Jun 3, 2025
Maddy AI version diff · 1 comparison

What changed between versions

Raised Bill → GL Joint Favorable Substitute · 4 edits
MODERATE
The bill was renamed from a 'Raised Bill' to a 'Substitute Bill' and expanded its title to include devices and nonlegend drugs. The most significant substantive change is the addition of a requirement for the Department of Consumer Protection to create public-private partnerships to import specific drugs (levonorgestrel, mifepristone, and misoprostol) and their similar active ingredients, alongside existing regulations for nonsterile compounding pharmacies. The bill also includes new reporting requirements for pharmaceutical marketing firms and the department.
Scope change
The bill's scope was expanded from solely concerning prescription drugs to also include devices and nonlegend drugs.
SCOPE

The bill title was updated to include 'devices and nonlegend drugs' in addition to prescription drugs.

REQUIREMENT

Added a new requirement for the Department of Consumer Protection to establish public-private partnerships to import levonorgestrel, mifepristone, misoprostol, and similar active ingredients.

Added a new requirement for the Department of Consumer Protection to compile and publish an annual report on pharmaceutical marketing firm activities by December 31, 2024, and annually thereafter.

TECHNICAL

The bill was renumbered from 'Raised Bill No. 1355' to 'Substitute Bill No. 1355' and the page count was updated from 6 pages to 31 pages.

Floor votes · Senate May 20, 2025

How they voted

24–11
Passed · 1 other
Total votes 36
May 20, 2025
D Democratic25
24 Yea 1
96% Yea
R Republican11
11 Nay
100% Nay
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
23
Key actions
6
Committee
4
Amendments
3
Jun 3, 2025
Lower · Passed
BILL PASSED TEMPORARILY
lower
May 20, 2025
Upper · Passed
SEN. PASSED, SEN. AMEND. SCH. A
upper
May 20, 2025
Amended
SEN. REJ. SEN. AMEND. SCH. C
upper
May 20, 2025
Amended
SEN. REJ. SEN. AMEND. SCH. B
upper
May 20, 2025
Upper · Passed
SEN. ADOPTED SEN. AMEND. SCH. A
upper
May 12, 2025
Upper · Passed
Joint Favorable
upper
May 8, 2025
Upper · Passed
IMMEDIATE TRANSMITTAL TO COMMITTEE
upper
Mar 24, 2025
Upper · Passed
Joint Favorable Substitute
upper
Feb 20, 2025
Committee
REF. TO JOINT COMM. ON General Law
upper
0 primary · 0 co-sponsors

Sponsors

No sponsor information available.